Install
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
- 913articles · 365d
- 1+ day agolatest article
- Sep 14, 2025earliest in window
- 95%with images
- 285avg words
- Medical 573
- Business & Industrial 538
- Economy, Business & Finance 451
- Health & Wellness 337
- Health 267
- Finance & Business 254
- Science & Technology 156
- Science & Nature 42
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Zeno???s Paradox, Orphan Product Access and the Future of Unmet Need
3+ day, 13+ hour ago (364+ words) Unmet need is likely a new battlefield impacting prior authorization. CMS ACCESS Model: Changing the Landscape of Disease Management Orphan Product Risk Contracting Future Phase III Trial Planning: Payer Point of View Zeno’s paradox is a riddle about motion and…...
How ClaimGuardRx's Purpose-Built AI Detects and Counters Diversion Tactics
4+ day, 21+ hour ago (124+ words) Pharmaceutical Executive Sponsored by Paysign Bryan Dennison, Senior Vice President of Sales and Product at Paysign, explains the technical foundation of ClaimGuardRx, a proprietary large language model (LLM) trained specifically on patient affordability claim patterns rather than adapted from a general-purpose…...
Unlocking the Future of Real-World Data & Research | PharmExec
5+ day, 1+ hour ago (40+ words) Unlocking the Future of Real-World Data & Research Pharmaceutical Executive Pharmaceutical Executive Daily: Moonwalk Biosciences' $70 Million Series B Trusted Research Environments Are Reshaping Real-World Data Access: Q&A with Mark Cziraky FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults...
Trusted Research Environments Are Reshaping Real-World Data Access: Q&A with Mark Cziraky
1+ week, 1+ hour ago (497+ words) Pharmaceutical Executive The pharma and biotech industries run on data, especially on the R&D side Data is one of the most valuable assets, but it can also cause some of the biggest headaches Due to the wide array of…...
Exploring the Real Reasons Why RBQM Implementation Fails
1+ week, 5+ day ago (78+ words) Pharmaceutical Executive RBQM implementations fail not because the software is wrong — but because the human environment surrounding it was never engineered. There is a myth in our industry that when an RBQM implementation fails to deliver the cause must be…...
Exec on Execs: Compliance Burdens
2+ week, 1+ hour ago (67+ words) Pharmaceutical Executive Exec on Execs: Compliance Burdens The Full Path of Drug Development, and Why So Few Drugs Make It: Q&A with Dr. Ying Huang Pharmaceutical Executive Daily: President Trump Planning New Medicaid Drug-Pricing Deals FDA Approves Daraxonrasib as…...
Why Global Science Innovation is Shifting to Asia | PharmExec
2+ week, 4+ day ago (57+ words) Why Global Science Innovation is Shifting to Asia Pharmaceutical Executive Pharmaceutical Executive Daily: FDA Approves Imaavy for wAIHA What Executives and Investors Are Looking for in Pharma Companies FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia in Patients Aged 12 and…...
What Executives and Investors Are Looking for in Pharma Companies
2+ week, 4+ day ago (258+ words) K2 Therapeutics CEO Ying Huang discusses the three priorities that define a successful biotech: unmet need, development cost, and accessible pricing. Earlier this year, Pharmaceutical Executive reported on China’s growing prominence in the pharma and biotech spaces. During this year, billions…...
Moving Beyond the Sample Size Guess: Lessons from 60 Million Clinical Trial Simulations
2+ week, 5+ day ago (118+ words) Pharmaceutical Executive Why traditional power calculations leave asset value on the table, and how adaptive frameworks change the math on risk. Most Phase 2 trials are sized on a guess seen as mathematics. You are in the trial design meeting, your…...
M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership
2+ week, 5+ day ago (647+ words) Pharmaceutical Executive...